Off-Label Use of Inhaled Nitric Oxide After Release of NIH Consensus Statement

201577 citationsJournal Article

Authors

Alan R. Spitzer · Mednax (United States)

Abstract

The rates of off-label iNO use in preterm infants continue to rise despite evidence revealing no clear benefit in this population. This pattern of iNO prescription is not benign and comes with economic consequences.

Topics & Keywords

Neonatal Respiratory Health Research Infant Development and Preterm Care Neuroscience of respiration and sleep

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PEDIATRICS

Volume 135, Issue 4, pp. 643-648

DOI: 10.1542/peds.2014-3290

Field-Weighted Citation Impact: 6.94